Welcome to our dedicated page for Omnicell Com news (Ticker: OMCL), a resource for investors and traders seeking the latest updates and insights on Omnicell Com stock.
Omnicell, Inc. (NASDAQ: OMCL) develops healthcare technology for autonomous medication management across pharmacy and nursing care settings. Its updates cover financial results, product bookings, recurring revenue, connected-device demand, and product launches such as Omnicell Titan XT and the OmniSphere platform.
Company news also includes healthcare conference presentations, customer engagement programs, clinical leadership roles, and innovation updates tied to automation, AI-enabled intelligence, software workflows, data analytics, and expert services for medication management in healthcare facilities.
EnlivenHealth, a division of Omnicell (OMCL), has launched a new Scope of Practice and Reimbursement Snapshot solution for Good Neighbor Pharmacy members. This innovative tool provides critical information on clinical services and reimbursement tailored to each state, empowering independent pharmacies to expand their clinical offerings and improve patient care.
The solution offers easy access to up-to-date information on approved clinical services, reimbursement activities, and medical billing codes. It aims to simplify the complex landscape of clinical services and billing, potentially driving operational efficiency and revenue growth for pharmacies. Good Neighbor Pharmacy members can access the solution through their AB Solutions Portal.
Omnicell (NASDAQ:OMCL) announced strong Q2 2024 results, exceeding guidance across all metrics. Total revenues were $277 million, down 7% year-over-year. GAAP net income was $0.08 per diluted share, while non-GAAP net income reached $0.51 per diluted share. The company reported $557 million in cash and cash equivalents and $571 million in total debt. Omnicell raised its 2024 non-GAAP EBITDA and earnings per share guidance, projecting full-year revenues between $1.070 billion and $1.110 billion. The company's XT Amplify program is gaining market momentum, and strategic partnerships are enhancing pharmacy performance. Omnicell remains focused on innovation and streamlining operations to drive long-term growth and shareholder returns.
Omnicell, Inc. (Nasdaq:OMCL), a leader in pharmacy care delivery transformation, has announced the release of its second quarter 2024 financial results on August 1, 2024, before the market opens. The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the results. Interested parties can join the call by dialing (800) 715-9871 in the U.S. or (646) 307-1963 internationally, using the Conference ID 3278878. A live and archived webcast will be available on Omnicell's Investor Relations website.
Omnicell, Inc. (OMCL) will be presenting at the BofA Securities 2024 Health Care Conference in Las Vegas, NV. The presentation will take place on May 15, 2024, at 3:40 p.m. PT. The event will be live-streamed and available for viewing on the Omnicell website.
Omnicell, Inc. (NASDAQ:OMCL) announced first quarter 2024 results, exceeding guidance with total GAAP revenues of $246 million. The company reported a challenging environment for some health system customers affecting revenues. Omnicell highlighted new solutions for their XT automated dispensing systems and ongoing efforts to enhance shareholder value. Financially, the company reported a net loss of $16 million, non-GAAP net income of $1 million, and non-GAAP EBITDA of $11 million. With a strong balance sheet, Omnicell aims to transform the pharmacy care delivery model and continues to innovate in the industry.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.